Payment overview · 2025
General Payments
$657.06
12 reported records · 5 companies
Healthcare provider profile · identity verified
Yong Wang, MD
Allopathic & Osteopathic Physicians|Internal Medicine · EL MONTE, CA · NPI 1326056888
Verified facts
What the public records show
CMS Open Payments records show Yong Wang, MD received $657.06 in general payments during 2025 across 12 reported records.
AstraZeneca Pharmaceuticals LP accounted for 41.2% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 11 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Farxiga, Jardiance.
Amgen Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported PROLIA as an associated drug or biological on 20867 records involving 11744 distinct recipient NPIs. Public Medicare Part D data also shows 30 claims for Prolia by this doctor in 2024.
Astellas Pharma US Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Myrbetriq as an associated drug or biological on 16 records involving 16 distinct recipient NPIs. Public Medicare Part D data also shows 123 claims for Myrbetriq by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported BRILINTA as an associated drug or biological on 993 records involving 512 distinct recipient NPIs. Public Medicare Part D data also shows 12 claims for Brilinta by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 86 claims for Farxiga by this doctor in 2024.
Boehringer Ingelheim Pharmaceuticals, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 123636 records involving 49438 distinct recipient NPIs. Public Medicare Part D data also shows 379 claims for Jardiance by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $270.73 | 41.2% | 4 | 2025 |
| GlaxoSmithKline, LLC. | Unresolved — no canonical attribution shown | $175.54 | 26.7% | 4 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $167.31 | 25.5% | 2 | 2025 |
| Astellas Pharma US Inc | Unresolved — no canonical attribution shown | $24.18 | 3.7% | 1 | 2025 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $19.30 | 2.9% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $657.06 | 12 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| REPATHA Normalized: repatha |
Biological | Amgen Inc. | $167.31 | 2 | 2025 |
Source payment records
|
|||||
| AREXVY Normalized: arexvy |
Biological | GlaxoSmithKline, LLC. | $148.96 | 2 | 2025 |
Source payment records
|
|||||
| AIRSUPRA Normalized: airsupra |
Drug | AstraZeneca Pharmaceuticals LP | $125.36 | 2 | 2025 |
Source payment records
|
|||||
| BREZTRI Normalized: breztri |
Drug | AstraZeneca Pharmaceuticals LP | $125.00 | 1 | 2025 |
Source payment records
|
|||||
| BEXSERO Normalized: bexsero |
Biological | GlaxoSmithKline, LLC. | $26.58 | 2 | 2025 |
Source payment records
|
|||||
| PENMENVY Normalized: penmenvy |
Biological | GlaxoSmithKline, LLC. | $26.58 | 2 | 2025 |
Source payment records
|
|||||
| SHINGRIX Normalized: shingrix |
Biological | GlaxoSmithKline, LLC. | $24.93 | 1 | 2025 |
Source payment records
|
|||||
| Veozah Normalized: veozah |
Drug | Astellas Pharma US Inc | $24.18 | 1 | 2025 |
Source payment records
|
|||||
| OTEZLA Normalized: otezla |
Drug | Amgen Inc. | $22.95 | 1 | 2025 |
Source payment records
|
|||||
| FARXIGA Normalized: farxiga |
Drug | AstraZeneca Pharmaceuticals LP | $20.37 | 1 | 2025 |
Source payment records
|
|||||
| JARDIANCE Normalized: jardiance |
Drug | Boehringer Ingelheim Pharmaceuticals, Inc. | $19.30 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| FARXIGA farxiga |
2025 | Farxiga | 2024 | 86 | exact normalized | Medicare Part D |
| JARDIANCE jardiance |
2025 | Jardiance | 2024 | 379 | exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| Amgen Inc. Exact reporting entity; no affiliate inference |
2025 | PROLIA open payments reported associated product |
CMS Open Payments — General Payments 20867 supporting records · 11744 recipient NPIs · example record 1226874448 |
Prolia · 2024 Exact normalized brand match · 1 Part D row |
30 | 25 |
| Astellas Pharma US Inc Exact reporting entity; no affiliate inference |
2025 | Myrbetriq open payments reported associated product |
CMS Open Payments — General Payments 16 supporting records · 16 recipient NPIs · example record 1238599014 |
Myrbetriq · 2024 Exact normalized brand match · 1 Part D row |
123 | 15 |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | BRILINTA open payments reported associated product |
CMS Open Payments — General Payments 993 supporting records · 512 recipient NPIs · example record 1206131430 |
Brilinta · 2024 Exact normalized brand match · 1 Part D row |
12 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
86 | 19 |
| Boehringer Ingelheim Pharmaceuticals, Inc. Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 123636 supporting records · 49438 recipient NPIs · example record 1221811583 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
379 | 49 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 780 | 129 |
| Losartan Potassium | Losartan Potassium | 609 | 97 |
| Jardiance | Empagliflozin | 379 | 49 |
| Amlodipine Besylate | Amlodipine Besylate | 377 | 62 |
| Metoprolol Succinate | Metoprolol Succinate | 336 | 53 |
| Tamsulosin Hcl | Tamsulosin Hcl | 336 | 49 |
| Gabapentin | Gabapentin | 296 | 60 |
| Clopidogrel | Clopidogrel Bisulfate | 289 | 47 |
| Alendronate Sodium | Alendronate Sodium | 270 | 54 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 264 | 43 |
| Metformin Hcl | Metformin Hcl | 260 | 40 |
| Azelastine Hcl | Azelastine Hcl | 251 | 53 |
| Finasteride | Finasteride | 244 | 37 |
| Levothyroxine Sodium | Levothyroxine Sodium | 207 | 32 |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 165 | 47 |
| Donepezil Hcl | Donepezil Hcl | 162 | 29 |
| Omeprazole | Omeprazole | 160 | 34 |
| Simvastatin | Simvastatin | 159 | 24 |
| Glipizide | Glipizide | 145 | 22 |
| Myrbetriq | Mirabegron | 123 | 15 |
| Benazepril Hcl | Benazepril Hcl | 118 | 20 |
| Metformin Hcl Er | Metformin Hcl | 117 | 20 |
| Kerendia | Finerenone | 112 | 15 |
| Alcohol Pads | Alcohol Antiseptic Pads | 106 | 50 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 99 | 31 |
| Valsartan | Valsartan | 96 | 15 |
| Vascepa | Icosapent Ethyl | 96 | 17 |
| Diclofenac Sodium | Diclofenac Sodium | 95 | 41 |
| Clonidine Hcl | Clonidine Hcl | 93 | 43 |
| Celecoxib | Celecoxib | 89 | 20 |
| Tradjenta | Linagliptin | 87 | suppressed |
| Zolpidem Tartrate | Zolpidem Tartrate | 87 | 19 |
| Farxiga | Dapagliflozin Propanediol | 86 | 19 |
| Allopurinol | Allopurinol | 84 | 14 |
| Tramadol Hcl | Tramadol Hcl | 83 | 22 |
| Famotidine | Famotidine | 82 | 28 |
| Fluticasone Propionate | Fluticasone Propionate | 81 | 23 |
| Xarelto | Rivaroxaban | 81 | 15 |
| Eliquis | Apixaban | 80 | 13 |
| Procto-Med Hc | Hydrocortisone | 80 | 15 |
| Januvia | Sitagliptin Phosphate | 77 | suppressed |
| Chlorhexidine Gluconate | Chlorhexidine Gluconate | 72 | 25 |
| Pioglitazone Hcl | Pioglitazone Hcl | 72 | 11 |
| Lisinopril | Lisinopril | 69 | 11 |
| Sertraline Hcl | Sertraline Hcl | 69 | 12 |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 68 | suppressed |
| Cyclosporine | Cyclosporine | 67 | 12 |
| Alprazolam | Alprazolam | 64 | 14 |
| Glimepiride | Glimepiride | 63 | suppressed |
| Nitroglycerin | Nitroglycerin | 62 | 20 |
| Pantoprazole Sodium | Pantoprazole Sodium | 62 | suppressed |
| Furosemide | Furosemide | 61 | 12 |
| Meloxicam | Meloxicam | 60 | 17 |
| Montelukast Sodium | Montelukast Sodium | 57 | suppressed |
| Clotrimazole-Betamethasone | Clotrimazole/Betamethasone Dip | 55 | 27 |
| Janumet | Sitagliptin Phos/Metformin Hcl | 54 | suppressed |
| Memantine Hcl | Memantine Hcl | 54 | 12 |
| Azithromycin | Azithromycin | 53 | 47 |
| Methimazole | Methimazole | 53 | suppressed |
| Pregabalin | Pregabalin | 48 | suppressed |
| Omega-3 Acid Ethyl Esters | Omega-3 Acid Ethyl Esters | 47 | 12 |
| Nifedipine Er | Nifedipine | 46 | suppressed |
| Creon | Lipase/Protease/Amylase | 45 | suppressed |
| Hydralazine Hcl | Hydralazine Hcl | 45 | suppressed |
| Amiodarone Hcl | Amiodarone Hcl | 43 | suppressed |
| Carbidopa-Levodopa | Carbidopa/Levodopa | 41 | suppressed |
| Dapagliflozin | Dapagliflozin Propanediol | 39 | 15 |
| Dutasteride | Dutasteride | 38 | suppressed |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 38 | 11 |
| Metoprolol Tartrate | Metoprolol Tartrate | 38 | suppressed |
| Meclizine Hcl | Meclizine Hcl | 37 | 16 |
| Quetiapine Fumarate | Quetiapine Fumarate | 37 | suppressed |
| Carbidopa-Levodopa Er | Carbidopa/Levodopa | 36 | suppressed |
| Linzess | Linaclotide | 36 | suppressed |
| Icosapent Ethyl | Icosapent Ethyl | 35 | 13 |
| Temazepam | Temazepam | 34 | suppressed |
| Levetiracetam | Levetiracetam | 33 | suppressed |
| Ketoconazole | Ketoconazole | 32 | suppressed |
| Hydrochlorothiazide | Hydrochlorothiazide | 31 | suppressed |
| Prolia | Denosumab | 30 | 25 |
| Lorazepam | Lorazepam | 28 | suppressed |
| Potassium Chloride | Potassium Chloride | 28 | suppressed |
| Zenpep | Lipase/Protease/Amylase | 28 | suppressed |
| Alcohol Prep Pads | Alcohol Antiseptic Pads | 27 | 18 |
| Ammonium Lactate | Ammonium Lactate | 26 | suppressed |
| Ropinirole Hcl | Ropinirole Hcl | 26 | suppressed |
| Trazodone Hcl | Trazodone Hcl | 26 | suppressed |
| Namzaric | Memantine Hcl/Donepezil Hcl | 25 | suppressed |
| Tenofovir Disoproxil Fumarate | Tenofovir Disoproxil Fumarate | 25 | suppressed |
| Escitalopram Oxalate | Escitalopram Oxalate | 24 | suppressed |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 24 | suppressed |
| Novolin 70-30 Flexpen | Insulin Nph Hum/Reg Insulin Hm | 24 | suppressed |
| Memantine Hcl Er | Memantine Hcl | 23 | suppressed |
| Amoxicillin | Amoxicillin | 22 | 17 |
| Breztri Aerosphere | Budesonide/Glycopyr/Formoterol | 22 | suppressed |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 22 | suppressed |
| Baclofen | Baclofen | 21 | suppressed |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 21 | suppressed |
| Ibuprofen | Ibuprofen | 21 | 15 |
| Isosorbide Dinitrate | Isosorbide Dinitrate | 20 | suppressed |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 20 | suppressed |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 19 | 15 |
| Easy Touch Alcohol Prep Pads | Alcohol Antiseptic Pads | 18 | 11 |
| Carvedilol | Carvedilol | 17 | suppressed |
| Glipizide Er | Glipizide | 17 | suppressed |
| Mupirocin | Mupirocin | 17 | suppressed |
| Topiramate | Topiramate | 17 | suppressed |
| Acetaminophen-Codeine | Acetaminophen With Codeine | 16 | suppressed |
| Albuterol Sulfate | Albuterol Sulfate | 16 | suppressed |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 16 | suppressed |
| Levocetirizine Dihydrochloride | Levocetirizine Dihydrochloride | 16 | suppressed |
| Valsartan-Hydrochlorothiazide | Valsartan/Hydrochlorothiazide | 16 | suppressed |
| Breo Ellipta | Fluticasone/Vilanterol | 15 | suppressed |
| Cephalexin | Cephalexin | 15 | 13 |
| Ciclopirox | Ciclopirox | 15 | suppressed |
| Janumet Xr | Sitagliptin Phos/Metformin Hcl | 15 | suppressed |
| Prednisone | Prednisone | 15 | 13 |
| Ranolazine Er | Ranolazine | 15 | suppressed |
| Atenolol | Atenolol | 14 | suppressed |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 14 | 13 |
| Ofloxacin | Ofloxacin | 14 | 12 |
| Trulicity | Dulaglutide | 14 | suppressed |
| Benazepril-Hydrochlorothiazide | Benazepril/Hydrochlorothiazide | 13 | suppressed |
| Citalopram Hbr | Citalopram Hydrobromide | 13 | suppressed |
| Fenofibrate | Fenofibrate Nanocrystallized | 13 | suppressed |
| Hydrocortisone | Hydrocortisone | 13 | suppressed |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 13 | suppressed |
| Tizanidine Hcl | Tizanidine Hcl | 13 | 11 |
| Brilinta | Ticagrelor | 12 | suppressed |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 12 | suppressed |
| Nano 2nd Gen Pen Needle | Pen Needle, Diabetic | 12 | suppressed |
| Novolog Mix 70-30 Flexpen | Insulin Aspart Prot/Insuln Asp | 12 | suppressed |
| Risedronate Sodium | Risedronate Sodium | 12 | suppressed |
| Single Use Swab | Alcohol Antiseptic Pads | 12 | suppressed |
| Solifenacin Succinate | Solifenacin Succinate | 12 | suppressed |
| Amlodipine-Valsartan | Amlodipine Besylate/Valsartan | 11 | suppressed |
| Divalproex Sodium | Divalproex Sodium | 11 | suppressed |
| Duloxetine Hcl | Duloxetine Hcl | 11 | suppressed |
| Entecavir | Entecavir | 11 | suppressed |
| Metolazone | Metolazone | 11 | suppressed |
| Nebivolol Hcl | Nebivolol Hcl | 11 | suppressed |
| Oxybutynin Chloride | Oxybutynin Chloride | 11 | suppressed |
| Quetiapine Fumarate Er | Quetiapine Fumarate | 11 | suppressed |
| Repaglinide | Repaglinide | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $657.06 · 12 records | AstraZeneca Pharmaceuticals LP | AIRSUPRA, AREXVY, BEXSERO, BREZTRI, FARXIGA, JARDIANCE, OTEZLA, PENMENVY, REPATHA, SHINGRIX, Veozah | 5 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Farxiga play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with Amgen Inc.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error